Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CorMedix Inc. - Common Stock (NQ:CRMD)

12.50 -2.46 (-16.44%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CorMedix Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Concentrix Posts Downbeat Earnings, Joins CorMedix And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Stay updated with the stocks that are on the move in today's pre-market session.
The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
CorMedix Stock Tumbles After $85M Stock Sale; But Retail Sees Bargain In DefenCath Bet
The offering follows an upward revision to CorMedix’s Q2 revenue forecast, driven by faster-than-expected rollout of its FDA-approved DefenCath therapy across an extensive dialysis network. 
Via Stocktwits
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Earnings Scheduled For May 6, 2025
Via Benzinga
Earnings Preview For Cormedix
Via Benzinga
Get insights into the top gainers and losers of Thursday's after-hours session.
After the closing bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. 
Via Chartmill
Applied Materials To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
CorMedix Lifts Q2 Outlook As Dialysis Partner Expands DefenCath Use; Needham Raises PT To $20
DefenCath, CorMedix’s lead product, was launched in hospitals in April 2024 and in outpatient settings in July 2024 following FDA approval. 
Via Stocktwits
CorMedix Spikes To Four-Year High On A Surprise Deal For Its Leading Drug
CorMedix shares bounded to a four-year high Monday after the biotech company inked an expanded deal for its leading drug. 
Via Investor's Business Daily
CorMedix Stock Hits New 52-Week High On Updated Guidance: The Details
CorMedix Inc (NASDAQ:CRMD) shares are hitting new 52-week highs on Monday after the company raised its sales guidance for the second quarter. 
Via Benzinga
Kroger Posts Better-Than-Expected Earnings, Joins Couchbase, CarMax And Other Big Stocks Moving Higher On Friday
Via Benzinga
CorMedix Q1 Earnings Trump Estimates: Retail’s Overjoyed
The company reported net revenue of $39.1 million for the first quarter from the sales of DefenCath, above an analyst estimate of $36, as per Finchat data. 
Via Stocktwits
Topics Earnings Government
CorMedix Stock Rises After Preliminary Q1 Results Exceeds Expectations: Retail’s Elated
The company expects quarterly adjusted earnings before interest, taxes, depreciation, and amortisation (EBITDA) to exceed $22.5 million once final numbers are reported, exceeding expectations of $14.78... 
Via Stocktwits
Marvell Technology, Nvidia, Tesla, Apple And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
CORMEDIX ALERT: Bragar Eagel & Squire, P.C. is Investigating CorMedix Inc. on Behalf of CorMedix Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
CorMedix (CRMD) Q4 2024 Earnings Call Transcript
CRMD earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
Which stocks are experiencing notable movement on Tuesday?
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Let's uncover which stocks are experiencing notable gaps during today's session.
The market is buzzing with gapping stocks on Tuesday. Let's uncover which stocks are experiencing notable gaps during today's session. 
Via Chartmill
CorMedix Stock Loses Almost A Third Of Its Market Cap After Downbeat H1 Revenue Outlook – But Retail Shrugs It Off
The company reported earnings of $0.22 per share compared with a loss of $0.26 per share in the corresponding period of 2023, owing to the launch of its lead product, DefenCath. 
Via Stocktwits
Nasdaq Gains 50 Points; US New Home Sales Rise In February
Via Benzinga
Which stocks are moving before the opening bell on Tuesday?
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
Earnings Scheduled For March 25, 2025
Via Benzinga
CorMedix Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Via Benzinga
Li Auto, Xponential Fitness And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Healthcare Stocks Doing Well But SMID Biotech Looking A Little Frazzled
Small caps took another step down this past week as geopolitical events dampened sentiment. 
Via Talk Markets
Topics ETFs Stocks / Equities
3 Value Stocks That Are Backed By The World’s Largest Activist Hedge Fund
Sometimes, hedge funds make risky decisions. But these stocks are at the lower end of the exposure risk spectrum. 
Via Talk Markets
Topics Stocks / Equities
Top movers in Friday's after hours session
As the regular session of the US market concludes on Friday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
Elliott Investment Management Buys Wolfspeed Stock, Bets Against Nvidia In Q4
Elliott Investment Management made several portfolio moves in the fourth quarter, closing multiple options positions and shaking up the activist firm's technology exposure. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.